Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse

Molecular Psychiatry

Volumn 19, Issue 11, 2014, Pages 1235-1242

  Kim, S H ^a   Steele, J W ^a,f   Lee, S W ^b   Clemenson, G D ^b   Carter, T A ^c,g   Treuner, K ^c,h   Gadient, R ^c,i   Wedel, P ^c,j   Glabe, C ^d   Barlow, C ^c,k   Ehrlich, M E ^a   Gage, F H ^b   Gandy, S ^a,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c BrainCells Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h SEQUENOM INC   (United States)

ⁱ R Gadient Pharma Consulting   (United States)

^j Lumena Pharmaceuticals Inc   (United States)

^k PARKINSON S INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; AMYLOID PRECURSOR PROTEIN; METABOTROPIC RECEPTOR ANTAGONIST; MGS 0210; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; APP PROTEIN, HUMAN; METABOTROPIC RECEPTOR; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC DRUG ADMINISTRATION; COGNITION; CONTROLLED STUDY; DENTATE GYRUS; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TOLERABILITY; ELEVATED PLUS MAZE TEST; HIPPOCAMPUS; LEARNING; LONG TERM CARE; MOUSE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPHARMACOLOGY; NONHUMAN; RECOGNITION; SPATIAL LEARNING; WORKING MEMORY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANXIETY; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; LEARNING; NEUROGENESIS; PSYCHOTROPIC DRUGS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84908498932     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.87     Document Type: Article

References (54)

1. Gandy S, Dekosky ST. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med 2013; 64: 367-383.
2. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
3. Flood DG, Coleman PD. Hippocampal plasticity in normal aging and decreased plasticity in Alzheimer's disease. Prog Brain Res 1990; 83: 435-443.
4. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
5. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
6. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci USA 1997; 94: 7942-7947.
7. Kim SH, Fraser PE, Westaway D St, George-Hyslop PH, Ehrlich ME, Gandy S. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. J Neurosci 2010; 30: 3870-3875.
8. Lee HG, Ogawa O, Zhu X, O'Neill MJ, Petersen RB, Castellani RJ et al. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol 2004; 107: 365-371.
9. Campo B, Kalinichev M, Lambeng N, El Yacoubi M, Royer-Urios I, Schneider M et al. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet 2011; 25: 152-166.
10. Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 2004; 46: 907-917.
11. Shimazaki T, Iijima M, Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 2004; 501: 121-125.
12. Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006; 186: 587-593.
13. Yoshimizu T, Chaki S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 2004; 315: 493-496.
14. Lilja AM, Rojdner J, Mustafiz T, Thome CM, Storelli E, Gonzalez D et al. Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-beta levels. PLoS One 2013; 8: e58752.
15. Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci 2013; 33: 15596-15602.
16. Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010; 142: 39-51.
17. Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther 2013; 5: 25.
18. Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM et al. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 2008; 59: 568-580.
19. Demars M, Hu YS, Gadadhar A, Lazarov O. Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice. J Neurosci Res 2010; 88: 2103-2117.
20. Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 2006; 495: 70-83.
21. Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 2002; 83: 1509-1524.
22. Rodriguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, LaFerla FM et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One 2008; 3: e2935.
23. Verret L, Jankowsky JL, Xu GM, Borchelt DR, Rampon C. Alzheimer's-Type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci 2007; 27: 6771-6780.
24. Wang R, Dineley KT, Sweatt JD, Zheng H. Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis. Neuroscience 2004; 126: 305-312.
25. Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG et al. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol 2004; 188: 224-237.
26. Zhang C, McNeil E, Dressler L, Siman R. Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. Exp Neurol 2007; 204: 77-87.
27. Lazarov O, Marr RA. Neurogenesis and Alzheimer's disease: at the crossroads. Exp Neurol 2010; 223: 267-281.
28. Marlatt MW, Lucassen PJ. Neurogenesis and Alzheimer's disease: biology and pathophysiology in mice and men. Curr Alzheimer Res 2010; 7: 113-125.
29. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener 2011; 6: 85.
30. Winner B, Kohl Z, Gage FH. Neurodegenerative disease and adult neurogenesis. Eur J Neurosci 2011; 33: 1139-1151.
31. Veeraraghavalu K, Sisodia SS. Mutant presenilin 1 expression in excitatory neurons impairs enrichment-mediated phenotypes of adult hippocampal progenitor cells. Proc Natl Acad Sci USA 2013; 110: 9148-9153.
32. Gadient RA, Wedel P, Friesbie V, Leuchter AF, Targum SD, Truong C et al. Safety, Pharmacokinetic and Pharmacodynamic Profile of BCI-632, A Selective Metabotropic Glutamate 2/3 Receptor Antagonist, in Healthy Human Subjects. Society for Neuroscience: New Orleans, LA, 2012 Program no. 841.820.
33. Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 2010; 68: 220-230.
34. Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci 2007; 27: 13376-13383.
35. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009; 35: 352-358.
36. Zhao C, Teng EM, Summers RG Jr., Ming GL, Gage FH. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci 2006; 26: 3-11.
37. Nakamura M, Kawakita Y, Yasuhara A, Fukasawa Y, Yoshida K, Sakagami K et al. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0] hexane-2,6-dicarboxylic Acid), a potent metabotropic glutamate receptor antagonist. Drug Metab Dispos 2006; 34: 369-374.
38. Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S et al. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg Med Chem 2006; 14: 4193-4207.
39. Shimazaki T, Kaku A, Chaki S. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur J Pharmacol 2007; 575: 94-97.
40. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004; 46: 457-467.
41. Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A et al. Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett 2005; 378: 131-134.
42. Baddeley AD, Bressi S, Della Sala S, Logie R, Spinnler H. The decline of working memory in Alzheimer's disease. A longitudinal study. Brain 1991; 114: 2521-2542.
43. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46: 130-135.
44. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33: 403-408.
45. Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 2010; 11: 339-350.
46. Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry 2012; 18: 889-897.
47. Lagace DC, Donovan MH, DeCarolis NA, Farnbauch LA, Malhotra S, Berton O et al. Adult hippocampal neurogenesis is functionally important for stress-induced social avoidance. Proc Natl Acad Sci USA 2010; 107: 4436-4441.
48. Henneman WJ, Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox NC et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009; 72: 999-1007.
49. Kohler SJ, Williams NI, Stanton GB, Cameron JL, Greenough WT. Maturation time of new granule cells in the dentate gyrus of adult macaque monkeys exceeds six months. Proc Natl Acad Sci USA 2011; 108: 10326-10331.
50. Mela F, Marti M, Fiorentini C, Missale C, Morari M. Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-Type high voltage activated Ca++ channels and endogenous dopamine. Mol Cell Neurosci 2006; 31: 284-292.
51. Pisani A, Bonsi P, Catania MV, Giuffrida R, Morari M, Marti M et al. Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci 2002; 22: 6176-6185.
52. ClinicalTrials.gov [Internet]. 29 February 2000. Identifier NCT01546051, A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers. National Library of Medicine (US): Bethesda (MD), 2012 Available from http://www.clinicaltrials.gov/ct2/show/NCT01546051.
53. ClinicalTrials.gov [Internet]. 29 February 2000. Identifier NCT01548703, A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers. National Library of Medicine (US): Bethesda (MD), 2012 Available from http://www.clinicaltrials.gov/ct2/show/NCT01548703.
54. Gandy S. Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. N Engl J Med 2012; 367: 864-866.